机构:
Emory Univ, Kathleen B & Mason I Lowance Ctr Human Immunol &, Atlanta, GA 30322 USAEmory Univ, Kathleen B & Mason I Lowance Ctr Human Immunol &, Atlanta, GA 30322 USA
Goronzy, Joerg J.
[1
]
Weyand, Cornelia M.
论文数: 0引用数: 0
h-index: 0
机构:
Emory Univ, Kathleen B & Mason I Lowance Ctr Human Immunol &, Atlanta, GA 30322 USAEmory Univ, Kathleen B & Mason I Lowance Ctr Human Immunol &, Atlanta, GA 30322 USA
Weyand, Cornelia M.
[1
]
机构:
[1] Emory Univ, Kathleen B & Mason I Lowance Ctr Human Immunol &, Atlanta, GA 30322 USA
T-cell activation and differentiation depend on the signal strength received by the T-cell receptor and on signals provided by costimulatory molecules. The most prominent co-stimulatory molecule is CD28, which controls the activation of naive and memory T cells by antigen presented on professional antigen-presenting cells. Blocking of the CD28-CD80/86 pathway has been an appealing strategy for inducing tolerance in autoimmune diseases where the disease-inducing autoantigens are not known. Although CD28 has maintained its unique position, the past decade has witnessed the recognition that a large number of regulatory molecules on T cells must be stimulated to generate a fully protective immune response. These regulatory receptors differ in their preferential expression on T-cell subsets, in the ligands that they recognize, and in the signaling pathways that they trigger. They have in common the fact that they provide information on the cellular environment in which the T-cell response occurs. By intercepting these signals, we may be able to influence disease-relevant T-cell responses in autoimmune diseases while potentially minimizing broad immunosuppression.